TT232, a novel signal transduction inhibitory compound in the therapy of cancer and inflammatory diseases

Orsolya Szokolóczi, Richárd Schwab, I. Peták, L. Őrfi, A. Pap, Alex N. Eberle, Tamás Szüts, G. Kéri

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

TT-232 is a structural analogue of somatostatin exhibiting strong and selective growth-inhibitory effects, inhibition of neurogenic inflammation, as well as general anti-inflammatory and analgesic potential without the wide-ranging endocrine side effects of the parent hormone and its "traditional" analogues. The anti-inflammatory action of TT-232 is mediated through the SSTR4 receptor, and its antitumor activity is mediated through the SSTR1 receptor and by the tumor-specific isoform of pyruvate kinase. Its mechanism of action is in line with a new era of molecular medicine called signal transduction therapy, where "false" intracellular or intercellular communication is inhibited or corrected without interfering with basic cell functions and machinery. TT232 has passed phase I clinical trials without toxicity and significant side effects, and phase II studies are running for oncological and anti-inflammatory indications, respectively. This compound has the perspective to become the first drug in molecularly targeted therapy of inflammation where a combined effect of anti-inflammatory, analgesic, and neurogenic inflammation-inhibiting activity can be achieved.

Original languageEnglish
Pages (from-to)217-235
Number of pages19
JournalJournal of Receptors and Signal Transduction
Volume25
Issue number4-6
DOIs
Publication statusPublished - 2005

Fingerprint

Neurogenic Inflammation
Signal transduction
Non-Steroidal Anti-Inflammatory Agents
Signal Transduction
Anti-Inflammatory Agents
Molecular Medicine
Clinical Trials, Phase I
Pyruvate Kinase
Somatostatin
Medicine
Machinery
Toxicity
Tumors
Neoplasms
Protein Isoforms
Hormones
Inflammation
Communication
Therapeutics
Growth

Keywords

  • Analogue
  • Anti-inflammatory
  • Apoptosis
  • Clinical trial
  • Neurogenic inflammation
  • Signal transduction inhibitor
  • Somatostatin
  • TT232

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

TT232, a novel signal transduction inhibitory compound in the therapy of cancer and inflammatory diseases. / Szokolóczi, Orsolya; Schwab, Richárd; Peták, I.; Őrfi, L.; Pap, A.; Eberle, Alex N.; Szüts, Tamás; Kéri, G.

In: Journal of Receptors and Signal Transduction, Vol. 25, No. 4-6, 2005, p. 217-235.

Research output: Contribution to journalArticle

@article{cb6a5fba5d544fc4be0a5b57fc233bd1,
title = "TT232, a novel signal transduction inhibitory compound in the therapy of cancer and inflammatory diseases",
abstract = "TT-232 is a structural analogue of somatostatin exhibiting strong and selective growth-inhibitory effects, inhibition of neurogenic inflammation, as well as general anti-inflammatory and analgesic potential without the wide-ranging endocrine side effects of the parent hormone and its {"}traditional{"} analogues. The anti-inflammatory action of TT-232 is mediated through the SSTR4 receptor, and its antitumor activity is mediated through the SSTR1 receptor and by the tumor-specific isoform of pyruvate kinase. Its mechanism of action is in line with a new era of molecular medicine called signal transduction therapy, where {"}false{"} intracellular or intercellular communication is inhibited or corrected without interfering with basic cell functions and machinery. TT232 has passed phase I clinical trials without toxicity and significant side effects, and phase II studies are running for oncological and anti-inflammatory indications, respectively. This compound has the perspective to become the first drug in molecularly targeted therapy of inflammation where a combined effect of anti-inflammatory, analgesic, and neurogenic inflammation-inhibiting activity can be achieved.",
keywords = "Analogue, Anti-inflammatory, Apoptosis, Clinical trial, Neurogenic inflammation, Signal transduction inhibitor, Somatostatin, TT232",
author = "Orsolya Szokol{\'o}czi and Rich{\'a}rd Schwab and I. Pet{\'a}k and L. Őrfi and A. Pap and Eberle, {Alex N.} and Tam{\'a}s Sz{\"u}ts and G. K{\'e}ri",
year = "2005",
doi = "10.1080/10799890500464621",
language = "English",
volume = "25",
pages = "217--235",
journal = "Journal of Receptor and Signal Transduction Research",
issn = "1079-9893",
publisher = "Informa Healthcare",
number = "4-6",

}

TY - JOUR

T1 - TT232, a novel signal transduction inhibitory compound in the therapy of cancer and inflammatory diseases

AU - Szokolóczi, Orsolya

AU - Schwab, Richárd

AU - Peták, I.

AU - Őrfi, L.

AU - Pap, A.

AU - Eberle, Alex N.

AU - Szüts, Tamás

AU - Kéri, G.

PY - 2005

Y1 - 2005

N2 - TT-232 is a structural analogue of somatostatin exhibiting strong and selective growth-inhibitory effects, inhibition of neurogenic inflammation, as well as general anti-inflammatory and analgesic potential without the wide-ranging endocrine side effects of the parent hormone and its "traditional" analogues. The anti-inflammatory action of TT-232 is mediated through the SSTR4 receptor, and its antitumor activity is mediated through the SSTR1 receptor and by the tumor-specific isoform of pyruvate kinase. Its mechanism of action is in line with a new era of molecular medicine called signal transduction therapy, where "false" intracellular or intercellular communication is inhibited or corrected without interfering with basic cell functions and machinery. TT232 has passed phase I clinical trials without toxicity and significant side effects, and phase II studies are running for oncological and anti-inflammatory indications, respectively. This compound has the perspective to become the first drug in molecularly targeted therapy of inflammation where a combined effect of anti-inflammatory, analgesic, and neurogenic inflammation-inhibiting activity can be achieved.

AB - TT-232 is a structural analogue of somatostatin exhibiting strong and selective growth-inhibitory effects, inhibition of neurogenic inflammation, as well as general anti-inflammatory and analgesic potential without the wide-ranging endocrine side effects of the parent hormone and its "traditional" analogues. The anti-inflammatory action of TT-232 is mediated through the SSTR4 receptor, and its antitumor activity is mediated through the SSTR1 receptor and by the tumor-specific isoform of pyruvate kinase. Its mechanism of action is in line with a new era of molecular medicine called signal transduction therapy, where "false" intracellular or intercellular communication is inhibited or corrected without interfering with basic cell functions and machinery. TT232 has passed phase I clinical trials without toxicity and significant side effects, and phase II studies are running for oncological and anti-inflammatory indications, respectively. This compound has the perspective to become the first drug in molecularly targeted therapy of inflammation where a combined effect of anti-inflammatory, analgesic, and neurogenic inflammation-inhibiting activity can be achieved.

KW - Analogue

KW - Anti-inflammatory

KW - Apoptosis

KW - Clinical trial

KW - Neurogenic inflammation

KW - Signal transduction inhibitor

KW - Somatostatin

KW - TT232

UR - http://www.scopus.com/inward/record.url?scp=30344440802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30344440802&partnerID=8YFLogxK

U2 - 10.1080/10799890500464621

DO - 10.1080/10799890500464621

M3 - Article

C2 - 16393913

AN - SCOPUS:30344440802

VL - 25

SP - 217

EP - 235

JO - Journal of Receptor and Signal Transduction Research

JF - Journal of Receptor and Signal Transduction Research

SN - 1079-9893

IS - 4-6

ER -